W Peter Hansen

Title: W Peter Hansen: Innovator in Plasmonic Nanoparticle Immunoassay Method

Introduction

W Peter Hansen is a notable inventor based in Drury, MA (US). He has made significant contributions to the field of immunoassay methods, particularly through his innovative approach involving plasmonic nanoparticles. His work has the potential to enhance the detection and classification of cell types in fluid samples.

Latest Patents

W Peter Hansen holds a patent for a method titled "Plasmonic nanoparticle immunoassay method." This method is designed for detecting a target cell surface molecule and classifying cell types in a fluid sample. The process involves adding a reagent that contains nanoparticles with optical plasmonic resonances and at least one fluorescent probe. These nanoparticles serve as a bio-optical probe for the target cell surface molecule, while each fluorescent probe is aimed at a specific cell classification marker. The method also includes acquiring images using dark field microscopy and fluorescence microscopy to detect and quantify the presence or absence of cells in the fluid sample that possess the target cell surface molecule or the cell classification marker. W Peter Hansen has 1 patent to his name.

Career Highlights

W Peter Hansen is associated with The General Hospital Corporation, where he applies his expertise in developing advanced diagnostic methods. His work is instrumental in pushing the boundaries of medical technology and improving patient outcomes through innovative solutions.

Collaborations

W Peter Hansen has collaborated with notable colleagues, including Conor L Evans and Robert A Hoffman. These partnerships have contributed to the advancement of research and development in the field of immunoassays.

Conclusion

W Peter Hansen's contributions to the field of immunoassay methods through his plasmonic nanoparticle approach exemplify the impact of innovation in medical diagnostics. His work continues to pave the way for advancements in detecting and classifying cell types, ultimately benefiting the healthcare industry.